Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Eloro Resources Ltd. (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) Announce New Mining Updates; Confirm Timeline for NI-43101 Compliant MRE Report Publication

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mining company focused on developing its potential world-class Iska Iska silver-tin polymetallic property located in the Potosi Department in southern Bolivia, recently updated the market with updated assay results derived from the company’s ongoing reconnaissance drilling. Recent drilling work across 16 holes, spread across […]

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming submission of an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial, dubbed HYPER-H23-1. The study, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in […]

Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN), a clinical-stage company, is focused on developing cellular therapy primarily for conditions with a clear unmet medical need. The company is guided by the mission to advance cell-based product candidates into pivotal Phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product. Longeveron has so far made […]

Leadership Changes At SOHM, Inc. (SHMN) to Strengthen Growth Strategies for Generic Drug Market and Gene Editing Platform Development

Generic drug manufacturing and distributing innovator SOHM (OTC: SHMN) is strengthening its governing team with the addition of two experienced visionaries committed to helping the company’s growth in the pharmaceutical, nutraceutical, and cosmeceutical marketplace. Dr. Krishna Bhat (MD, Ph.D, FACC), an experienced bioscientist and cardiologist, will bring his leadership skills to the company’s advisory board […]

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause […]

RJD Green Inc. (RJDG) Strongly Positioned with Diversified “Recession Resistant” Portfolio

Diversification is critical to investment success for many reasons: stable returns, risk reduction, and protection against market volatility. With these principles in mind, RJD Green (OTC: RJDG) a holding company, manages assets in three diverse, high-growth industries in separate “recession-resistant” markets, including construction, digital healthcare services, and environmental solutions. RJDG formed its specialty construction division […]

D-Wave Quantum Inc. (NYSE: QBTS) Delivers Power of Quantum to Solve Business Optimization Problems

Business leaders today are faced with a myriad of solutions to consider for integration into their organization’s IT infrastructure, many of which are critical in achieving meaningful operational efficiency and business advantage. One of the most promising yet perplexing solutions is quantum computing. Most businesses are faced with a vast array of optimization problems, but […]

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis. Nearly 50% of people with psoriasis experience moderate to severe symptoms (https://ibn.fm/jgqwh). The psoriasis treatment market was valued at $16.45 billion in 2022 and […]

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth

Lexaria Bioscience (NASDAQ: LEXX), a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform, continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits […]

Shoals Technologies Group, Inc. (NYSE: SHLS) Featured in Coverage of the ROTH MKM 10th Annual Solar & Storage Symposium

Shoals Technologies Group (NYSE: SHLS) is a leading provider of electrical balance of systems (“EBOS”) solutions for solar, storage, and electric vehicle charging infrastructure. Since its founding in 1996, the company has introduced innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability. […]

 

From Our Blog

SS Innovations International, Inc. (NASDAQ: SSII) CEO Outlines Growth Strategy as SSi Mantra Expands Robotic Surgery, Telesurgery, and Global Reach

November 6, 2026

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is seeing increased adoption of its SSi Mantra surgical robotic platform, with CEO Dr. Sudhir Srivastava telling The Motley Fool’s interviewer Rachel Warren that the company’s commercial growth reflects a combination of technological capabilities, clinical experience and affordability (https://ibn.fm/EJk05). During the interview, Srivastava […]

Rotate your device 90° to view site.